Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015
- PMID: 30713046
- PMCID: PMC6401262
- DOI: 10.1016/j.mayocp.2018.08.041
Incidence of AL Amyloidosis in Olmsted County, Minnesota, 1990 through 2015
Abstract
Objective: To determine the incidence of immunoglobulin light chain amyloidosis (AL amyloidosis) in a strictly defined geographic area from 1990 through 2015.
Patients and methods: We searched a computerized database for the records of all Olmsted County, Minnesota, residents with a diagnosis of AL amyloidosis from January 1, 1990, through December 31, 2015. In addition, records of all residents with a mention of amyloidosis were obtained from the Rochester Epidemiology Project, which contains the medical records of Mayo Clinic and Olmsted Medical Group. The diagnosis of AL amyloidosis was determined by mass spectrometry, immunohistochemical analysis, or positive Congo red staining.
Results: Thirty-five patients were identified as having AL amyloidosis. The median age at diagnosis was 76 years (range, 38-90 years), with men accounting for 54%. The incidence rate of AL amyloidosis from 1990 through 2015 adjusted for age and sex was 1.2 per 100,000 person-years (95% CI, 0.8-1.6 per 100,000 person-years). Rates were similar across the decades 1990-1999, 2000-2009, and 2010-2015 at 1.1, 0.9, and 1.6 per 100,000 person-years, respectively, with no suggestion of an increasing rate during the 26 years. There was a trend toward an increasing incidence over time from 1950 through 2015 in Olmsted County, but it was not significant (P=.15). Applying the rate of 1.2 per 100,000 person-years to the US population of 321 million in 2015, one would expect 3852 new cases of AL amyloidosis in the United States each year.
Conclusion: The incidence of AL amyloidosis in Olmsted County has not changed significantly in the past 66 years.
Copyright © 2018 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.
Conflict of interest statement
Conflicts of Interest Disclosure: Dr. Dispenzieri has research support from Prothena, Jannsen, Alnylam, Celgene, Takeda, Pfizer and GSK. Dr. Kumar has research grants for clinical trials to the institution: Celgene, Takeda, Janssen, BMS, Sanofi, KITE, Merck, Abbvie, Medimmune, Novartis, Roche-Genentech and Amgen. Consulting with no personal payments: Celgene, Takeda, Janssen, KITE, Merck, Abbvie, Medimmune,Genentech, Oncopeptides and Amgen. IRC chair: Oncopeptides. Honorarium: Dr. Reddys Lab. The other authors have nothing to disclose.
Figures
Comment in
-
Robert A. Kyle, MD: Lessons From a Legend.Mayo Clin Proc. 2019 Mar;94(3):375-376. doi: 10.1016/j.mayocp.2019.01.030. Mayo Clin Proc. 2019. PMID: 30832784 No abstract available.
-
New Insights Into a Multifaceted Disease.Mayo Clin Proc. 2019 Mar;94(3):388-390. doi: 10.1016/j.mayocp.2019.01.029. Mayo Clin Proc. 2019. PMID: 30832787 No abstract available.
References
-
- Kyle RA, Bayrd ED. “Primary” systemic amyloidosis and myeloma. Discussion of relationship and review of 81 cases. Arch Intern Med 1961;107344–353. - PubMed
-
- Kyle RA, Greipp PR. Amyloidosis (AL). Clinical and laboratory features in 229 cases. Mayo Clinic Proceedings 1983;58(10):665–683. - PubMed
-
- Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Seminars in Hematology 1995;32(1):45–59. - PubMed
-
- Kyle RA, Linos A, Beard CM, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. [see comment]. Blood 1992;79(7):1817–1822. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources